Сумма биотехнологии. Руководство по борьбе с мифами о генетической модификации растений, животных и людей

337. Ferreira A. et al.: Sickle hemoglobin confers tolerance to Plasmodium infection. Cell 2011, 145(3):398–409.

338. Gao Z. et al.: An estimate of the average number of recessive lethal mutations carried by humans. Genetics 2015, 199(4):1243–54.

339. Novotna M. et al.: Toxoplasma and reaction time: role of toxoplasmosis in the origin, preservation and geographical distribution of Rh blood group polymorphism. Parasitology 2008, 135(11): 1253–61.

340. Pappas G. et al.: Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol 2009, 39(12):1385–94.

341. Flegr J. et al.: Increased incidence of traffic accidents in Toxoplasma-infected military drivers and protective effect RhD molecule revealed by a large-scale prospective cohort study. BMC Infect Dis 2009, 9:72.

342. Hart R., Norman R.J.: The longer-term health outcomes for children born as a result of IVF treatment: Part I – General health outcomes. Hum Reprod Update 2013, 19(3):232–43.

343. Hart R., Norman R.J.: The longer-term health outcomes for children born as a result of IVF treatment. Part II – Mental health and development outcomes. Hum Reprod Update 2013, 19(3):244–50.

344. Brinton L.A. et al.: In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertil Steril 2013, 99(5):1189–96.

345. Reigstad M.M. et al.: Risk of breast cancer following fertili ty treatment – a registry based cohort study of parous women in Norway. Int J Cancer 2015, 136(5):1140–8.

346. Fan H.C. et al.: Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Science USA 2008, 105(42):16266–71.

347. Schneider A. et al.: Population-based Tay-Sachs screening among Ashkenazi Jewish young adults in the 21st century: Hexosaminidase A enzyme assay is essential for accurate testing. Am J Med Genet A 2009, 149A(11):2444–7.

348. Cao A. et al.: Control of beta-thalassaemia by carrier screening, genetic counselling and prenatal diagnosis: the Sardinian experience. Ciba Found Symp 1996, 197:137–51; discussion 51–5.

349. White G. et al.: Clinical evaluation of recombinant factor IX. Semin Hematol 1998, 35(2 Suppl 2):33–8.

350. Sands M.S.: AAV-mediated liver-directed gene therapy. Methods Mol Biol 2011, 807:141–57.

351. Nathwani A.C. et al.: Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014, 371(21):1994–2004.

352. Cavazzana-Calvo M. et al.: Gene therapy of human severe combined immunodeficiency (SCID) – X1 disease. Science 2000, 288(5466):669–72.

353. Hacein-Bey-Abina S. et al.: A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med 2014, 371(15):1407–17.

354. Ivics Z. et al.: Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997, 91(4):501–10.

355. Collier L.S., Largaespada D.A.: Transposons for cancer gene discovery: Sleeping Beauty and beyond. Genome Biol 2007, 8 Suppl 1:S15.

356. Aronovich E.L. et al.: The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet 2011, 20(R1):R14–20.

357. Schmitt T.M. et al.: T cell receptor gene therapy for cancer. Hum Gene Ther 2009, 20(11):1240–8.

358. Clay T.M. et al.: Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999, 163(1):507–13.

359. Roth J.A. et al.: p53 tumor suppressor gene therapy for cancer. Oncology (Williston Park) 1999, 13(10 Suppl 5):148–54.

360. Chen G.X. et al.: Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. Onco Targets Ther 2014, 7:1901–9.

361. Collin S.P., Trezise A.E.: The origins of colour vision in vertebrates. Clin Exp Optom 2004, 87(4–5):217–23.

362. Jacobs G.H.: Evolution of colour vision in mammals. Philos Trans R Soc Lond B Biol Sci 2009, 364(1531):2957–67.

363. Panchin A.Y. et al.: Asymmetric and non-uniform evolution of recently duplicated human genes. Biol Direct 2010, 5:54.

364. Yokoyama S. et al.: Molecular basis of spectral tuning in the redand green-sensitive (M/LWS) pigments in vertebrates. Genetics 2008, 179(4):2037–43.

365. Deeb S. et al.: Structure-function relationships in human red/green color vision. Documenta Ophthalmologica Proceedings Series 1993, 56:13–7.

366. Jordan G. et al.: The dimensionality of color vision in carriers of anomalous trichromacy. J Vis 2010, 10(8):12.

367. Mancuso K. et al.: Gene therapy for red-green colour blindness in adult primates. Nature 2009, 461(7265):784–7.

368. Simonelli F. et al.: Gene therapy for Leber’s congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010, 18(3):643–50.